# A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

> **NCT07721259** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Washington** · enrollment: 60 (estimated)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Triple-Negative Breast Carcinoma

## Interventions

- **BIOLOGICAL:** CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- **DRUG:** Recombinant Granulocyte-Macrophage Colony-Stimulating Factor
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT07721259
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2029-07-16
- **Final completion:** 2030-07-16
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07721259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07721259, "A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07721259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*